Ani Pharmaceuticals (ANIP) Net Income towards Common Stockholders (2011 - 2026)

Ani Pharmaceuticals has disclosed Net Income towards Common Stockholders across 16 years of filings, most recently posting $24.7 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders rose 203.33% year-over-year to $24.7 million; the TTM figure through Jun 2026 stood at $108.0 million (up 1011.99% YoY), while the FY2025 annual figure was $77.2 million, up 483.08% from the prior year.
• Net Income towards Common Stockholders came in at $24.7 million for Q2 2026 at Ani Pharmaceuticals, down from $29.5 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $29.5 million in Q1 2026 to a low of -$24.6 million in Q3 2024.
• Average Net Income towards Common Stockholders over 5 years is $4.4 million, with a median of $3.4 million recorded in 2023.
• Year-over-year, Net Income towards Common Stockholders slumped 25451.85% in 2022 and soared 1623.23% in 2024.
• Over 5 years, Net Income towards Common Stockholders stood at -$4.6 million in 2022, then soared by 116.11% to $749000.0 in 2023, then sank by 1526.17% to -$10.7 million in 2024, then surged by 357.35% to $27.5 million in 2025, then declined by 10.16% to $24.7 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $24.7 million in Q2 2026, $29.5 million in Q1 2026, and $27.5 million in Q4 2025.